MAP1LC3A and myotonic dystrophy type 1: Rapamycin, an mTOR inhibitor, promoted LC3 lipidation in the DM1-derived fibroblasts (Figure 1A,B) but not in muscle tissue from HSALR mice [9]; however, it was reported to sufficiently improve muscle function.